I have now conducted this simple survey with over 5000 parents at conferences around the world with similar findings trusted 1 mg arimidex. The Committee has heard moving testimony from parents in support of this belief order arimidex 1 mg with amex, as well as from parent-advocates proven arimidex 1mg. When she testified before the Committee in April of 2000, her autistic son, Liam, was four years old. He was constantly taking off his shoes; he screamed if we dressed or undressed him; he would stare for hours in front of the television and would not move if you blocked the view. He did not want to sing any of his favorite songs; he would cover his ears and scream `No. A One Year Update ; Hearing Before the Committee on Government th Reform; 107 Congress; April 25-26, 2001;page 17;Serial No. My question to you is: How long does it take for a coincidence to surface time and time and time again, case after case after case, before it can become a viable hypothesis, especially when the solution to solving the 92 problem seems so apparent? Her testimony made equally clear her conviction that her son s autism was related to a series of vaccinations given on the same day: Jacob met every developmental milestone that first year, right along with Jesse. The following 24 hours, both twins slept most of the time, with over 100-degree temperatures, in spite of receiving the recommended Tylenol dosage every 6 hours. He would spend long periods of time studying the way their wheels would spin or whether or not they were lined up just right. Any attempt to interrupt or distract him was met with great resistance and an eventual fit. During this time, Jesse continued to progress, starting to talk and interact with all the children around him. The final blow was the adverse reaction to the host of vaccines he received 16 months later. While we do not know this to be specifically proved at this time, we should not ignore the body of evidence that calls into question the source of many children with autism. Many parents of autistic children have filed petitions for compensation or lawsuits against vaccine manufacturers. Not surprisingly, suspicions that there may be a causal relationship between some vaccines and autism have spawned a significant amount of litigation. It has been estimated that as many as 3,000 to 5,000 such 96 petitions may be filed in the near future. The Federal government maintains a trust fund out of which awards are paid and which is funded by an excise tax on vaccines. Petitions for compensation are adjudicated before a team of special masters, with the Justice Department representing the Federal government. First, a general causation inquiry known as the Omnibus Autism Proceeding will be conducted to determine generally if vaccines can cause autism disorders, and if so, under what circumstances. In the second part of the two-part procedure, the Special 97 Master s determination in the omnibus proceeding will be applied to individual cases. The second alleges that the mercury contained in several other vaccines caused neurological damage, 98 resulting in autism spectrum disorders. These contentions are summarized in the Master Autism Petition For Vaccine Compensation filed by the families: As a direct result of one or more vaccinations covered under the National Vaccine Injury Compensation Program, the vaccine in question has developed a neurodevelopmental disorder, consisting of an Autism Spectrum Disorder or a similar disorder. The first such lawsuit was filed in Texas in May of 2001 on behalf of five-year-old Joseph Alexander Counter (Counter v. According to his parents and attorneys, he was diagnosed with autism and then was found to 100 have high levels of mercury exposure. Later that year, a group of law firms calling themselves the Mercury Vaccine Alliance filed class action lawsuits in 101 nine different states. While dozens of lawsuits have been filed, they generally fall into three different categories: 1. Actions claiming that thimerosal is an adulterant or a contaminant in a vaccine; 2. Actions seeking compensation for loss of consortium (love and companionship) on behalf of parents of autistic children; and 97 Id. Class actions seeking compensation for autistic children and medical monitoring for broad populations of children who were exposed to mercury in vaccines. However, one exception allows lawsuits for vaccine injuries allegedly caused by an adulterant or a 102 contaminant intentionally added to the vaccine. In twin decisions in May of 2002, a Federal judge ruled that thimerosal could not be considered an adulterant or a contaminant, and claims filed on that basis were dismissed. A Growing Number of Scientists and Doctors Believe That a Relationship Between Thimerosal in Vaccines and Autism Spectrum Disorders is Plausible A. Introduction A growing number of respected scientists and researchers are convinced that there is a relationship between the use of thimerosal in childhood vaccines and the growing incidence of autism. At the same time, senior officials from Federal health care agencies and other public health experts continue to insist that there is no evidence of such a relationship. First, concerns about the use of thimerosal in vaccines existed in public health agencies for more than two decades before action was taken to remove them from vaccines. The lethargic response to these legitimate concerns will be discussed in the following section of this report. Second, much more research needs to be done before any conclusive determinations can be made about vaccines and autism spectrum disorders. Developing more and better research data will be critically important to resolving the legal disputes over compensation for children with autism, and restoring the confidence of the American public in vaccines. This section will review the current state of the scientific debate over vaccines and autism. American Home products, et al; Order of District Court Judge Samuel Kent; May 7, 2002. The common thread linking both reports was the conclusion that much more research needed to be done before firm conclusions could be drawn. However, the authors cautioned that if the vaccine triggered autistic disorders among a small number of children who were predisposed to an adverse reaction, the population studies that had been done to-date would be too imprecise to detect them: It is important to recognize the inherent methodological limitations of such studies in establishing causality. Studies may not have sufficient precision to detect very rare occurrences on a population level. A poor understanding of the risk factors and failure to use a standard case definition may also hamper the 105 ability of epidemiological studies to detect rare adverse events. They also called for targeted studies to follow up on a groundbreaking series of case studies by Dr. Andrew Wakefield of Great Britain, who determined that 12 British children who suffered from autism spectrum disorders and chronic bowel 106 inflammation also had vaccine-strain measles virus in their tissues. Wakefield published further research with larger patient populations further supporting a correlation between low level measles infection in the intestions and the onset of autism and subsequently entercolitis. They did, however, state that such a connection is biologically plausible, and recommended much more research on the issue. The report summarized: The committee concludes that although the hypothesis that ex posure to thimerosal-containing vaccines could be associated with neurodevelopmental disorders is not established and rests on indirect and incomplete information, primarily from analogies with methylmercury and levels of maximum mercury exposure from vaccines given in children, the hypothesis is biologically 108 plausible. The report specifically cited the influenza vaccine, the diphtheria-tetanus toxoid vaccine, and some nasal sprays. They urged that, full consideration be given by appropriate professional societies and government agencies to removing thimerosal from vaccines administered to infants, children or pregnant women in the United States. Finally, the report recommended that numerous types of research be conducted to help the scientific community better determine if there is a causal relationship between thimerosal and autism or other disorders. A Growing Number of Researchers Believe That There May be a Relationship Between Vaccines and Autism Spectrum Disorders A growing number of researchers and medical professionals believe that there may be a link between the mercury preservative used in vaccines and autism spectrum disorders and other neurodevelopmental disorders. Few, if any, would make such a statement categorically until more research is done. However, judging by testimony received by the Committee, many researchers believe that this hypothesis is plausible based on work they have done to-date. They believe that this is a promising field of research that may yield breakthroughs on the question of the underlying causes of the growing incidence of autism and other neurodevelopmental disorders. Haley, who is the Chairman of the Chemistry Department at the University of Kentucky. Haley summarized his views in this way: I cannot say, nor would I say, that vaccinations cause autism. However, if the data holds up that I have been seeing with the relationship, I think it is an awfully good suspect, at least one of the co-factors that might aid in the onset of this disease. Haley described his laboratory research on thimerosal: I was requested to do an evaluation of the potential toxicity of vaccines containing thimerosal as a preservative versus those vaccines not containing thimerosal. The results were very dramatic as shown in the accompanying Table attached to this document.
These may include the use of solvent-detergent treatment generic arimidex 1mg with visa, which inactivates enveloped viruses ( 75) discount 1mg arimidex otc, pasteurization (76) 1mg arimidex visa, or low pH (77). Because the average half-life of IgG in the circulation is about 21 days, infusions are usually given every 3 to 4 weeks. The dose should be individualized to control infections and other symptoms but usually falls in a range of 300 to 600 mg/kg/dose, with the higher doses often being given at the longer dosing intervals. Serum IgG concentrations determined at the trough, just before the next infusion, can be used to provide an index and to assist decisions about the adequacy of dose and treatment interval but should not by themselves be used as an end point. These patients often require full replacement doses to remain free from infection despite having pretreatment serum IgG levels on the border of or within the normal range. Antibody-deficient patients with active acute or chronic infection may experience severe systemic symptoms, including shaking chills and spiking fevers, and inflammatory reactions at the site of infection (e. It may therefore be preferable to defer initiation of treatment until a satisfactory course of antibiotics is given in such patients. These are not true anaphylactic reactions, are not mediated by IgE, and are frequently associated with increased rather than decreased blood pressure. Such reactions can usually be treated by decreasing the rate of infusion or by administration of diphenhydramine, acetaminophen, or aspirin. Patients who demonstrate consistent patterns of reactions can be kept at slower rates for subsequent infusions or pretreated with the previously mentioned drugs. True anaphylaxis is extremely uncommon but has been reported in a very small number of patients with IgA deficiency who have IgE antibodies against IgA (79). Late adverse reactions include headache, which occasionally may have features of migraine; nausea, and fever, and may occur up to 48 hours after the infusion. Patients with recurrent febrile reactions should be carefully evaluated for the presence of chronic infection, which should be treated with appropriate antibiotics. We usually establish the safety, maximally tolerated rate, and need for premedication in our clinic before allowing the patient to go to home care. An advantage of the subcutaneous infusion method is that it makes self-administration feasible, especially if a small portable pump is used (81). Although prevention of acute, severe bacterial infections is the major goal of antibody replacement therapy, freedom from the symptoms of chronic infections in bronchiectasis can often be achieved, and many patients report amelioration of other symptoms such as arthralgia or arthritis when appropriate replacement has been achieved. This is most likely to involve delayed development of T-independent antibody responses such as those to bacterial capsular polysaccharides. We find it best to try such interruptions of therapy during the summer months, when the exposure to droplet-spread respiratory infection is reduced. In our experience, children whose IgG levels or specific antibody responses are not satisfactory by the time they have reached 5 years of age are not likely to improve in subsequent years, and this exercise is rarely productive above that age. Although the former may be relatively straightforward to detect in early infancy, common variable immunodeficiency disease and specific antibody deficiencies may present with symptoms of recurrent or chronic respiratory or gastrointestinal infections at any age. The pattern of infections and the associated historical and physical features may provide important clues to the underlying diagnosis and should be kept in mind as a progression through screening and specialized and definitive laboratory tests is pursued. Therapeutic efforts aimed at minimizing the morbidity from infection or correcting the underlying problem will be suggested by the specific diagnosis and should be individualized. Because subclinical chronic infection that can lead to long-term pulmonary damage may be present (36) and because there is an increased incidence of malignancy in patients with primary immune deficiencies ( 5,29), close follow-up is necessary. With advances in our understanding of the basic pathogenesis of these disorders at a molecular level, additional specific therapies lie just over the horizon. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Hyper-IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder. The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immune deficiency. Concentrations of antibodies in paired material and infant sera: relationship to IgG subclass. Hypogammaglobulinemia associated with normal or increased IgM (the hyper IgM syndrome): a case series review. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. Asplenia syndrome: insight into embryology through an analysis of cardiac and extracardiac anomalies. IgG subclass determination in the diagnosis and management of antibody deficiency syndromes. Human immunodeficiency virus infection induces both polyclonal and virus-specific B-cell activation. Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. In vitro analysis of humoral immunity in antibody deficiency with normal immunoglobulins. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. Application of carrier testing to genetic counseling for x-linked agammaglobulinemia. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. Adenosine deaminase deficiency with late onset of recurrent infectious: response to treatment with poly ethylene glycol-modified adenosine deaminase. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. In 1906, Clemons von Pirquet correctly predicted that immunity and hypersensitivity reactions would depend on the interaction between a foreign substance and the immune system, and that immunity and hypersensitivity would have similar underlying immunologic mechanisms (1). The search for the factor responsible for immediate hypersensitivity reactions became a subject of intense investigation over several years. In 1921, Prausnitz and Kstner (2) described the transfer of immediate hypersensitivity (to fish protein) by serum to the skin of a normal individual. This test for the serum factor responsible for immediate hypersensitivity reactions was termed the Prausnitz-Kstner test. Variations of this test remained the standard for measuring skin sensitizing antibody over the next 50 years. In 1925, Coca and Grove (3) extensively studied the skin-sensitizing factor from sera of patients with ragweed hay fever. They called skin-sensitizing antibody atopic reagin because of its association with hereditary conditions and because of their uncertainty as to the nature of the antibody involved. Thereafter, this factor was called atopic reagin, reaginic antibody, or skin-sensitizing antibody. This antibody clearly had unusual properties and could not be measured readily by standard immunologic methods. Major research efforts from the 1920s through the 1960s defined its physical and chemical properties and measured its presence in allergic individuals (4,5). In 1967, the Ishizakas (6) discovered that skin-sensitizing antibody belonged to a unique class of immunoglobulin, which they called immunoglobulin E (IgE). In elegant studies using immunologic techniques, they clearly demonstrated that reagin-rich serum fractions from a patient with ragweed hay fever belonged to a unique class of immunoglobulin (6). In 1969, cooperative studies between these workers and Ishizakas confirmed that the proteins were identical and that a new class of immunoglobulin, IgE, had been discovered ( 7).
H. Nefarius. University of Central Florida.
Richmond Rascals. 12 Richmond Hill. Richmond-Upon-Thames. TW10 6QX tel: 020 8948 2250